图片说明：示意图
图片来源：Public Domain（公有领域）
Global Justice Now周六发布的数据显示，自新的COVID变体Omicron出现以来，"仅有8名辉瑞和Moderna的顶级股东 "及其CEO就赚了103.1亿美元，但发现该变体的医生说它很温和，甚至可能有用。
塞斯-汉考克
【中国观察2021年12月09日讯】
据《共同梦想》报道，在11月24日至12月1日期间，Moderna的股票跳涨了13.61%--273.39美元至310.61美元，而辉瑞的股票上涨了7.41%--50.91美元至54.68美元。
根据总部设在英国的Global Justice Now编制的数据，在Omicron变体的消息登上头条后的一周内，Moderna和辉瑞公司的首席执行官和主要股东总共赚了103.1亿美元。
据《共同梦想》报道，在11月24日至12月1日期间，Moderna的股票跳涨了13.61%--273.39美元至310.61美元，而辉瑞公司的股票上涨了7.41%--50.91美元至54.68美元。
Moderna首席执行官Stéphane Bancel的股份从61亿美元增加到69亿美元，收益为8.24亿美元。辉瑞公司首席执行官阿尔伯特-伯拉的收益为339,291美元。
据《每日邮报》报道，加上首席执行官，Moderna和辉瑞公司的四位顶级股东赚了约51.6亿美元。
辉瑞公司的最大股东包括Vanguard Group（17.2亿美元）、Blackrock（14.6亿美元）、State Street Corp. (11亿美元）和资本世界投资者（9.09亿美元）。
今天购买。小罗伯特-肯尼迪的新书--《真实的安东尼-福西》。
Moderna的最大股东是Baillie Gifford & Co. (15.9亿美元)、Vanguard Group(10亿美元)、Blackrock(9.991亿美元)和Flagship Pioneering(6.537亿美元)。
正如《卫报》11月30日报道的那样，关于Omicron的早期新闻报道使疫苗制造商的股票飙升，此前Moderna和辉瑞公司表示他们正急于开发针对这种新变体的疫苗。
Moderna公司的股票在感恩节后的星期五--一个短暂的交易日--上涨了20%，而辉瑞公司及其疫苗合作伙伴BioNTech的股票分别上涨了6%和14%。
没有证据表明我们需要奥米克朗的疫苗，但辉瑞公司还是提出了这个理由
Global Justice Now指责大药厂通过吞噬向富裕国家出售疫苗的利润，同时拒绝分享专利并确保低收入国家获得COVID疫苗，从而对Omicron的出现负责。
该组织的制药业活动家蒂姆-比尔利说。
"制药公司知道，荒诞的疫苗不平等程度将为新变种的出现创造首要条件。他们让COVID-19在低收入和中等收入国家有增无减。而现在，这些制药公司的执行官和股东正在从他们帮助制造的危机中获利。这完全是骇人听闻"。
但并不是每个人都同意，不接种疫苗会导致新的变种出现，或者说奥米加是危险的。
Angelique Coetzee博士被认为是发现Omicron变体的人，她说她相信该变体可能有助于实现群体免疫。
担任南非医学协会主席的Coetzee在过去33年里一直是一名普通医生，她说Omicron的症状到目前为止似乎很温和。
紧急呼吁行动。告诉OMB你反对对联邦承包商进行强制性疫苗接种
科茨为《每日邮报》写道。
"据了解，南非这里没有人因Omicron变体而住院，也没有人被认为因它而病重......简单的事实是。如果像一些证据表明的那样，Omicron是一种快速传播的病毒，大多数感染者的症状都很轻微，这将是实现群体免疫的一个有用步骤。
早期数据支持Coetzee的观察，即虽然Omicron可能具有高度传染性，但它并不高度危险。
据CNBC报道，南非医学研究委员会在周六发布的一份报告中说，比勒陀利亚一家医院收治的大多数患COVID的病人不需要补充氧气。
该报告还指出，许多病人因其他医疗原因入院，然后被发现患有COVID。辉瑞公司首席执行官Bourla对这一消息的回应是告诉《华尔街日报》。
"我不认为有东西传播得快是个好消息。快速传播意味着它将出现在数十亿人身上，另一个突变可能出现。你不希望这样"。
尽管目前还不清楚是否需要新的疫苗，但Bourla说，辉瑞公司可以在2022年3月前开发出针对Omicron的疫苗。
Bourla说，需要几周的时间来确定目前的疫苗是否对该变种提供足够的保护。
https://childrenshealthdefense.org/defender/pfizer-moderna-shareholders-billions-richer-omicron/
Global Justice Now on Saturday released data showing “just eight top Pfizer and Moderna shareholders” and their CEOs made $10.31 billion since the new COVID variant, Omicron, emerged, but doctor who discovered it says it’s mild, and may even be useful.
By
Seth Hancock
Shares of Moderna jumped 13.61% — $273.39 to $310.61 — between Nov. 24 and Dec. 1, while Pfizer shares increased 7.41% — $50.91 to $54.68, Common Dreams reported.
Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.
In the week after news of the Omicron variant hit the headlines, the CEOs and major shareholders of Moderna and Pfizer made a combined $10.31 billion, according to data compiled by the UK-based Global Justice Now.
Shares of Moderna jumped 13.61% — $273.39 to $310.61 — between Nov. 24 and Dec. 1, while Pfizer shares increased 7.41% — $50.91 to $54.68, Common Dreams reported.
Moderna CEO Stéphane Bancel saw his shares increase from $6.1 billion to $6.9 billion, for a gain of $824 million. Albert Bourla, CEO of Pfizer, saw gains of $339,291.
Combined with the CEOs, Moderna’s and Pfizer’s four top shareholders made about $5.16 billion, The Daily Mail reported.
The top Pfizer shareholders include Vanguard Group ($1.72 billion), Blackrock ($1.46 billion), State Street Corp. ($1.1 billion) and Capital World Investors ($909 million).
BUY TODAY: Robert F. Kennedy, Jr.'s New Book — 'The Real Anthony Fauci'
Moderna’s top shareholders are Baillie Gifford & Co. ($1.59 billion), Vanguard Group ($1 billion), Blackrock ($999.1 million) and Flagship Pioneering ($653.7 million).
As The Defender reported Nov. 30, early news reports on Omicron sent vaccine makers’ stocks soaring, after Moderna and Pfizer said they were rushing to develop vaccines for the new variant.
Moderna’s stock rose 20% on the Friday following Thanksgiving — a short trading day — while Pfizer and its vaccine partner BioNTech saw respective gains of 6% and 14%.
No evidence we need a vaccine for Omicron, but Pfizer makes the case, anyway
Global Justice Now accused Big Pharma of being responsible for the emergence of Omicron by gobbling up profits selling vaccines to wealthy countries, while refusing to share patents and making sure low-income countries get access to COVID vaccines.
Tim Bierley, the organization’s pharma campaigner, said:
“Pharmaceutical companies knew that grotesque levels of vaccine inequality would create prime conditions for new variants to emerge. They let COVID-19 spread unabated in low- and middle-income countries. And now the same pharma execs and shareholders are making a killing from a crisis they helped to create. It’s utterly obscene.”
But not everyone agrees that failure to vaccinate causes new variants to emerge, or that Omicron is dangerous.
Dr. Angelique Coetzee, who is credited with discovering the Omicron variant, said she believes the variant may help lead to herd immunity.
Coetzee, who chairs the South African Medical Association and who has been a general practitioner for the last 33 years, said Omicron symptoms so far appear mild.
Urgent Call to Action: Tell OMB You Oppose Mandatory Vaccines for Federal Contractors
Coetzee wrote for The Daily Mail:
“No one here in South Africa is known to have been hospitalized with the Omicron variant, nor is anyone here believed to have fallen seriously ill with it … The simple truth is: We don’t know yet anywhere near enough about Omicron to make such judgments or to impose such policies … If, as some evidence suggests, Omicron turns out to be a fast-spreading virus with mostly mild symptoms for the majority of the people who catch it, that would be a useful step on the road to herd immunity.”
Early data support Coetzee’s observation that while Omicron may be highly infectious, it’s not highly dangerous.
According to CNBC, the South African Medical Research Council, in a report released Saturday, said most patients admitted to a hospital in Pretoria who had COVID didn’t need supplemental oxygen.
The report also noted that many patients were admitted for other medical reasons and were then found to have COVID. Pfizer CEO Bourla responded to that news by telling the Wall Street Journal:
“I don’t think it’s good news to have something that spreads fast. Spreads fast means it will be in billions of people and another mutation may come. You don’t want that.”
Though it’s not clear whether there’s a need for a new shot, Pfizer can develop a vaccine that targets Omicron by March 2022, Bourla said.
It will take a few weeks to determine whether the current vaccines provide enough protection against the variant, Bourla said.